Medical device maker NICO Corporation announced the enrollment of the first patient in the ENRICH (Early MiNimally-invasive Removal of ICH) randomized clinical trial. The trial will examine the procedural safety as well as economic and functional benefit of early surgical removal of intracerebral hemorrhages using its BrainPath Approach system. “Our initial clinical results with this approach for early clot removal have been exciting and provided a wake-up call to what has been missing in hemorrhagic stroke care,” trial principal investigator Dr. Daniel Barrow said in a press release.
Multi-center 300-patient trial
ENRICH is a multi-center trial sponsored by NICO and led by the Emory Stroke Center of Emory University hospitals and the Marcus Stroke & Neuroscience Center of Grady Memorial Hospital. The 300-patient trial is unique in that the multi-disciplinary teams of stroke neurology, neurosurgery and neuro-critical care physicians are participating at a minimum of 15 trial sites. Ideal trial candidates are spontaneous supratentorial ICH patients meeting established and well-defined criteria for study enrollment.
Source: PRNewswire | January 10, 2017